メンバー紹介

宮原　慶裕

教員名

宮原　慶裕（みやはら　よしひろ）　教授

リサーチセンター長

連絡先

〒514-8507　三重県津市江戸橋二丁目174番地
三重大学大学院医学系研究科
個別化がん免疫治療学
電話：059-231-5380／Fax：059-231-5397
Email：miyahr-y@med.mie-u.ac.jp

研究テーマ

個別化がん免疫療法、抗腫瘍免疫応答解析

プロフィール

三重大学医学部卒業後、第二内科入局。学位取得後にアメリカ　テキサス州ヒューストンBaylor College of Medicine, オハイオ州トレド　Toledo Universityに留学。　帰国後、三重大学大学院医学系研究科　がんワクチン講座　講師。2016年5月より遺伝子免疫細胞治療学講座　准教授。2018年3月より個別化がん免疫治療学講座　同職。

所属学会

日本癌学会、日本がん免疫学会、日本免疫学会、欧州遺伝子治療学会

著作・論文

  1. Oda H, Ishihara M, Miyahara Y, Nakamura J, Kozuka Y, Iwasa M, Tsunoda A, Yamashita Y, Saito K, Mizuno T, Shiku H, Katayama N. First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Rep Oncol. 2019 Feb 8;12(1):147-156.
  2. Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada S, Asai A, Ikeda H, Akiyoshi K, Harada N, and Shiku H. Antigen Delivery Targeting Tumor-Associated Macrophages Overcomes Tumor Immune Resistance. J Clin Invest. 2019 Mar 1;129(3):1278-1294.
  3. Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood. 2018 Sep 13;132(11):1134-1145.
  4. Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N. Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget. 2018 Feb 16;9(19):14909-14921.
  5. Wada M, Tsuchikawa T, Kyogoku N, Abiko T, Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer　Vaccination. Anticancer Res. 2018 Mar;38(3):1435-1444.
  6. Abiko T, Tsuchikawa T, Miyauchi K, Wada M, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncol Lett. 2018 Mar;15(3):3703-3711.
  7. Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017 Nov 2;130(18):1985-1994.
  8. Fujii K, Miyahara Y, Harada N, Muraoka D, Komura M, Yamaguchi R, Yagita H, Nakamura J, Sugino S, Okumura S, Imoto S, Miyano S, Shiku H. Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. Oncoimmunology. 2017 Mar 20;6(5):e1306617.
  9. Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncol Lett. 12(6):4493-4504. 2016
  10. Miyauchi K, Tsuchikawa T, Wada M, Abiko T, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy. 8(5):527-540, 2016.
  11. Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Working Group for CMC/Non-clinical Studies; Working Group for Cancer Vaccines and Adjuvants; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy; Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies.
    Cancer Sci. 106(12):1761-1771, 2015.
  12. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clin Cancer Res. 21(10):2268-2277, 2015.
  13. Schroder PM, Khattar M, Baum CE, Miyahara Y, Chen W, Vyas R, Muralidharan S, Mierzejewska B, Stepkowski SM.　PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy. Diabetologia.　58(6):1309-18. 2015.
  14. Khattar M, Miyahara Y, Schroder PM, Xie A, Chen W, Stepkowski SM. Interleukin-21 Is a Critical Regulator of CD4 and CD8 T Cell Survival during Priming under Interleukin-2 Deprivation Conditions. PLoS One. 9;9(1):e85882.2014
  15. Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. 11:246, 2013.
  16. Miyahara Y, Guo Z, Wang G, He X, Chen W, Stepkowski SM. A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells. J Immunol. 1;190(7):3153-62.2013.
  17. Miyahara Y, Khattar M, Schroder PM, Mierzejewska B, Deng R, Han R, Hancock WW, Chen W, Stepkowski SM.Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells. Am J Transplant. 12(6):1409-18.2012.
  18. Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, Shiku H. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Ther. 19(10):959-66.2012.
  19. Tsuda K, Yamanaka K, Linan W, Miyahara Y, Shiku H, Gabazza EC, Mizutani H. Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses. PLoS One. 6(12):e29020.2011.
  20. Wang G, Khattar M, Guo Z, Miyahara Y, Linkes SP, Sun Z, He X, Stepkowski SM, Chen W. IL-2-deprivation and TGF-beta are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation. Immunol Lett. 132:61-68, 2010.
  21. Miyahara Y, Wang G, Guo Z, Khattar M, Stepkowski SM, Chen W. “Default” Generation of Neonatal Regulatory T Cells. J Immunol. 185:71-78, 2010.
  22. Guo Z, Wang G, Miyahara Y, Khattar M, Linkes SP, Wang C, Xia J, Pan Y, Chen W, He X, Stepkowski SM. IL-7, but not thymic stromal lymphopoietin (TSLP), during priming enhances the generation of memory CD4(+) T cells. Immunol Lett. 128:116-123, 2010.